CollPlant Biotechnologies Ltd.
-
Ticker
CLGN
-
Industry
Biotechnology More
-
Sector
Healthcare More
- 11-50 Employees
- Based in Rehovot, Israel
CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. Their products are based on their rhCollagen (recombinant human collagen) that is produced with CollPlant's proprietary plant based genetic engineering technology. Their products address indications for the diverse fields of tissue repair, aesthetics and organ
…More manufacturing, and, they believe, are ushering in a new era in regenerative and aesthetic medicine. Their flagship rhCollagen BioInk product line is ideal for 3D bioprinting of tissues and organs. In October 2018, they entered into a licensing agreement with United Therapeutics, whereby United Therapeutics is using CollPlant's BioInks in the manufacture of 3D bioprinted lungs for transplant in humans.
CollPlant Biotechnologies Ltd.
Most Recent Responsibility Report
MOST RECENT
2024 ESG Report
Archived Responsibility Reports
Our service enables potential investors to review the most recent and archived CollPlant Biotechnologies Ltd. Sustainability Report, CollPlant Biotechnologies Ltd. Corporate Social Responsibility Report, CollPlant Biotechnologies Ltd. CSR Report, CollPlant Biotechnologies Ltd. Corporate Responsibility, CollPlant Biotechnologies Ltd. CR Report, CollPlant Biotechnologies Ltd. Citizenship Report, CollPlant Biotechnologies Ltd. ESG Report, and CollPlant Biotechnologies Ltd. Environmental Report online.